Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation.
Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Kebriaei P, Aljawai Y, Khan HN, Lee HC, Ye C, Patel KK, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Pasvolsky O, et al. Among authors: srour s. Blood Cancer J. 2024 May 17;14(1):82. doi: 10.1038/s41408-024-01062-2. Blood Cancer J. 2024. PMID: 38760362 Free PMC article.
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.
Pal SK, Tran B, Haanen JBAG, Hurwitz ME, Sacher A, Tannir NM, Budde LE, Harrison SJ, Klobuch S, Patel SS, Meza L, Dequeant ML, Ma A, He QA, Williams LM, Keegan A, Gurary EB, Dar H, Karnik S, Guo C, Heath H, Yuen RR, Morrow PK, Agarwal N, Srour SA. Pal SK, et al. Among authors: srour sa. Cancer Discov. 2024 Apr 5:OF1-OF14. doi: 10.1158/2159-8290.CD-24-0102. Online ahead of print. Cancer Discov. 2024. PMID: 38583184
Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation.
Alzahrani K, Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH. Alzahrani K, et al. Among authors: srour s. Br J Haematol. 2024 May;204(5):1944-1952. doi: 10.1111/bjh.19384. Epub 2024 Mar 6. Br J Haematol. 2024. PMID: 38448009
Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML.
Ciurea SO, Kongtim P, Srour S, Chen J, Soebbing D, Shpall E, Rezvani K, Nakkula R, Thakkar A, Troy EC, Cash AA, Behbehani G, Cao K, Schafer J, Champlin RE, Lee DA. Ciurea SO, et al. Among authors: srour s. Am J Hematol. 2024 May;99(5):890-899. doi: 10.1002/ajh.27281. Epub 2024 Mar 5. Am J Hematol. 2024. PMID: 38444268 Clinical Trial.
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial.
Khouri IF, Alzahrani K, Kantarjian H, Milton DR, Gulbis AM, Sasaki K, Jain N, Short NJ, Kadia T, Daher M, Rafei H, Im JS, Marin D, Olson AL, Popat U, Qazilbash M, Ramdial J, Rondon G, Srour S, Kebriaei P, Shpall E, Champlin R, Jabbour EJ. Khouri IF, et al. Among authors: srour s. Am J Hematol. 2024 May;99(5):836-843. doi: 10.1002/ajh.27254. Epub 2024 Feb 23. Am J Hematol. 2024. PMID: 38400519 Clinical Trial.
Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis.
Malek AE, Al-Juhaishi T, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Maadani F, Hosing C, Marin D, Kebriaei P, Rezvani K, Nieto Y, Anderlini P, Alousi AM, Faisal MS, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich VE, Ahmed S. Malek AE, et al. Among authors: srour sa. Bone Marrow Transplant. 2024 May;59(5):699-704. doi: 10.1038/s41409-024-02238-x. Epub 2024 Feb 14. Bone Marrow Transplant. 2024. PMID: 38355908 No abstract available.
Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation.
Marcoux C, Saliba RM, Wallis W, Khazal S, Ragoonanan D, Rondon G, Tewari P, Popat U, Oran B, Olson A, Bashir Q, Qazilbash M, Alousi A, Hosing C, Nieto Y, Alatrash G, Marin D, Rezvani K, Khouri I, Srour S, Champlin R, Shpall E, Kebriaei P. Marcoux C, et al. Among authors: srour s. Blood Adv. 2024 Mar 12;8(5):1128-1136. doi: 10.1182/bloodadvances.2023011233. Blood Adv. 2024. PMID: 38266155 Free PMC article.
Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience.
Pasvolsky O, Ghanem S, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Khan HN, Kebriaei P, Lee HC, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Pasvolsky O, et al. Among authors: srour s. Blood Cancer J. 2024 Jan 10;14(1):4. doi: 10.1038/s41408-023-00973-w. Blood Cancer J. 2024. PMID: 38199987 Free PMC article.
Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation.
Pasvolsky O, Pasyar S, Bassett RL, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Pasvolsky O, et al. Among authors: srour s. Cancer. 2024 May 1;130(9):1663-1672. doi: 10.1002/cncr.35171. Epub 2023 Dec 21. Cancer. 2024. PMID: 38127583
144 results